Thomas Fuchs-Buder
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thomas Fuchs-Buder has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
Denis Schmartz
Hôpital Erasme, Université Libre de Bruxelles, Bruxelles, Belgium
4 shared publications- Denis Schmartz
CHU Brugmann, Université Libre de Bruxelles, Bruxelles, Belgium
4 shared publications - Laurent Brunaud
Département de chirurgie viscérale, métabolique et cancérologique, Inserm N-GERE, CHRU de Nancy, université de Lorraine, 54000 Nancy, France
3 shared publications Peter Kranke
Klinik für Anästhesie und Intensivmedizin, Universitätsklinikum Würzburg, Würzburg, Deutschland
3 shared publications- Amit D. Raval
Bayer HealthCare Pharmaceuticals, Whippany, USA
2 shared publications Arash Afshari
2 shared publications
Latest Publications
- 5 November 2026
- Published by Springer Nature
- p. 127-151
Muskelrelaxanzien und Relaxometrie
- Open Access
- 15 August 2026
- Published by Wiley in Pediatric Anesthesia
- Vol. 36 (11) , 1437-1448
Current Use, Monitoring and Reversal of Neuromuscular Block in Pediatric Anesthesia and Intensive Care: A Web‐Based Cross‐Sectional ESAIC Survey
Background: Neuromuscular blocking agents are recommended by the European Society of Anaesthesiology and Intensive Care (ESAIC) and European Society of Paediatric Anaesthesia (ESPA) for facilitating tracheal intubation in children. Despite these recommendations, real‐world data on how neuromuscular blocking agents are used, monitored, and reversed remain scarce. Aims: To identify and characterize self‐reported neuromuscular blocking agent practice patterns across European and non‐European countries, in the period preceding publication of the joint ESAIC and ESPA guidelines. Methods: We conducted an anonymous, cross‐sectional survey between 12 November and 12 December 2025, targeting members of the ESAIC, ESPA, and the French and Spanish national pediatric anesthesiology societies involved in pediatric airway management across 43 countries. Results: The survey was accessed by 904 persons, and 874 responses were included in the analysis. Most participants were from Europe (83.5%) and worked in mixed pediatric anesthesia and intensive care settings (71.2%). Rocuronium was the most frequently used neuromuscular blocking agent for both routine tracheal intubation (68%; 95% CI 65%–71%) and rapid sequence intubation (67%; 95% CI 64%–70%). Neuromuscular blocking agents were used “always” or “mostly” before routine intubation in 47% of neonates (≤ 30 days) and 50% of infants (< 1 year), whereas “rarely” or “never” use was reported in 30% and 24%, respectively. Most respondents (56%) assessed adequacy of neuromuscular block using a fixed time interval after neuromuscular blocking agent administration. Reversal was administered “always” before extubation by 27% of respondents, while 9.3% reported “rarely” and 2.9% “never.” Only half of participants used quantitative neuromuscular monitoring to guide reversal. Sugammadex was used by 47%. Conclusions: Self‐reported clinical practice regarding neuromuscular blocking agent use in pediatric patients remains heterogeneous. Children are frequently intubated without neuromuscular blocking agents and extubated without consistent reversal. Quantitative neuromuscular monitoring remains uncommon. These practice patterns raise concerns for patient safety.
- 15 August 2026
- Published by Wiley in Pediatric Anesthesia
- Vol. 36 (11) , 1437-1448
Open AccessCurrent Use, Monitoring and Reversal of Neuromuscular Block in Pediatric Anesthesia and Intensive Care: A Web‐Based Cross‐Sectional ESAIC Survey
Background: Neuromuscular blocking agents are recommended by the European Society of Anaesthesiology and Intensive Care (ESAIC) and European Society of Paediatric Anaesthesia (ESPA) for facilitating tracheal intubation in children. Despite these recommendations, real‐world data on how neuromuscular blocking agents are used, monitored, and reversed remain scarce. Aims: To identify and characterize self‐reported neuromuscular blocking agent practice patterns across European and non‐European countries, in the period preceding publication of the joint ESAIC and ESPA guidelines. Methods: We conducted an anonymous, cross‐sectional survey between 12 November and 12 December 2025, targeting members of the ESAIC, ESPA, and the French and Spanish national pediatric anesthesiology societies involved in pediatric airway management across 43 countries. Results: The survey was accessed by 904 persons, and 874 responses were included in the analysis. Most participants were from Europe (83.5%) and worked in mixed pediatric anesthesia and intensive care settings (71.2%). Rocuronium was the most frequently used neuromuscular blocking agent for both routine tracheal intubation (68%; 95% CI 65%–71%) and rapid sequence intubation (67%; 95% CI 64%–70%). Neuromuscular blocking agents were used “always” or “mostly” before routine intubation in 47% of neonates (≤ 30 days) and 50% of infants (< 1 year), whereas “rarely” or “never” use was reported in 30% and 24%, respectively. Most respondents (56%) assessed adequacy of neuromuscular block using a fixed time interval after neuromuscular blocking agent administration. Reversal was administered “always” before extubation by 27% of respondents, while 9.3% reported “rarely” and 2.9% “never.” Only half of participants used quantitative neuromuscular monitoring to guide reversal. Sugammadex was used by 47%. Conclusions: Self‐reported clinical practice regarding neuromuscular blocking agent use in pediatric patients remains heterogeneous. Children are frequently intubated without neuromuscular blocking agents and extubated without consistent reversal. Quantitative neuromuscular monitoring remains uncommon. These practice patterns raise concerns for patient safety.
- 20 November 2025
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 144 (2) , 492-493
Let’s Say Goodbye to Acceleromyographic Twitch Monitoring: Comment
- 20 November 2025
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 144 (2) , 492-493
Let’s Say Goodbye to Acceleromyographic Twitch Monitoring: Comment
- Open Access
- 17 July 2025
- Published by Springer Nature in Journal of Clinical Monitoring and Computing
- Vol. 39 (5) , 801-803
Validity of neuromuscular monitoring: beyond the technology’s precision
- 17 July 2025
- Published by Springer Nature in Journal of Clinical Monitoring and Computing
- Vol. 39 (5) , 801-803
Open AccessValidity of neuromuscular monitoring: beyond the technology’s precision
- 24 June 2025
- Published by Wolters Kluwer Health in Current Opinion in Anaesthesiology
- Vol. 38 (4) , 349-352
Magnesium sulfate and sugammadex: implications for routine practice
Purpose of the review: Magnesium sulfate (MgSO4) enhances neuromuscular blockade; it may accelerate onset, prolong clinical duration, and delay neuromuscular recovery. In addition, MgSO4 administration shortly after neuromuscular recovery may lead to the recurrence of neuromuscular blockade. This review aimed to assess the efficacy and safety of sugammadex in both scenarios. Recent findings: Compelling evidence suggests that the dosing and timing of sugammadex administration remain unchanged whether the neuromuscular blockade is induced by rocuronium alone or results from magnesium pretreatment before rocuronium administration. Furthermore, particular caution is required when MgSO4 is administered shortly after recovery from neuromuscular blockade, as the reduced safety margin may lead to the reappearance of neuromuscular blockade. Sugammadex may also counteract this recurrence, provided that the initial neuromuscular blockade was induced by a steroidal neuromuscular blocking agent such as rocuronium or vecuronium. Summary: In both clinical scenarios, sugammadex-induced reversal is rapid and reliable.
- 24 June 2025
- Published by Wolters Kluwer Health in Current Opinion in Anaesthesiology
- Vol. 38 (4) , 349-352
Magnesium sulfate and sugammadex: implications for routine practice
Purpose of the review: Magnesium sulfate (MgSO4) enhances neuromuscular blockade; it may accelerate onset, prolong clinical duration, and delay neuromuscular recovery. In addition, MgSO4 administration shortly after neuromuscular recovery may lead to the recurrence of neuromuscular blockade. This review aimed to assess the efficacy and safety of sugammadex in both scenarios. Recent findings: Compelling evidence suggests that the dosing and timing of sugammadex administration remain unchanged whether the neuromuscular blockade is induced by rocuronium alone or results from magnesium pretreatment before rocuronium administration. Furthermore, particular caution is required when MgSO4 is administered shortly after recovery from neuromuscular blockade, as the reduced safety margin may lead to the reappearance of neuromuscular blockade. Sugammadex may also counteract this recurrence, provided that the initial neuromuscular blockade was induced by a steroidal neuromuscular blocking agent such as rocuronium or vecuronium. Summary: In both clinical scenarios, sugammadex-induced reversal is rapid and reliable.
- Open Access
- 28 March 2025
- Published by Springer Nature in Die Anaesthesiologie
- Vol. 74 (4) , 204-206
Neuromuskuläres Management: Bestandsaufnahme und Ausblick
- 28 March 2025
- Published by Springer Nature in Die Anaesthesiologie
- Vol. 74 (4) , 204-206
Open AccessNeuromuskuläres Management: Bestandsaufnahme und Ausblick
- Open Access
- 26 March 2025
- Published by MDPI AG in Anesthesia Research
- Vol. 2 (2) , 8
Deep Neuromuscular Blockade During General Anesthesia: Advantages, Challenges, and Future Directions
Background: Neuromuscular blocking agents play an important role in modern anesthesia by facilitating optimal surgical conditions through deep muscle relaxation. Additionally, neuromuscular monitoring and reversal ensure swift and reliable recovery from neuromuscular blockade. The evolution of neuromuscular blocking agents, from early curare derivatives to contemporary agents such as rocuronium and cisatracurium, has significantly enhanced the safety and efficacy of anesthesia. Methods: This review examines the historical development, pharmacological mechanisms, clinical applications, and innovations in managing neuromuscular blockade. Results: It underscores key milestones in the advancement of neuromuscular blockade, including the introduction of neuromuscular monitoring techniques like Train-of-Four, which improve patient safety by reducing residual neuromuscular blockade. Pharmacological advancements, particularly the emergence of sugammadex, have further revolutionized clinical practice by enabling rapid and reliable reversal of steroidal neuromuscular blocking agents. The discussion covers the role of deep neuromuscular blockade in optimizing surgical conditions, especially in minimally invasive procedures. Conclusion: Comparative analyses of standard versus deep blockade reveal potential advantages in certain surgical scenarios, although patient-specific factors and associated risks must be carefully evaluated. Future directions involve developing innovative neuromuscular blocking agents and reversal agents aimed at achieving faster onset, shorter duration, and fewer side effects. The management of neuromuscular blockade continues to evolve, propelled by advancements in pharmacology and monitoring technology. Anesthesiologists should embrace a personalized approach, integrating advanced monitoring tools and customized pharmacological strategies to enhance patient outcomes. Ongoing research into next-generation neuromuscular blocking agents and reversal agents holds the promise of further improving safety and efficiency in anesthesia practice.
- 26 March 2025
- Published by MDPI AG in Anesthesia Research
- Vol. 2 (2) , 8
Open AccessDeep Neuromuscular Blockade During General Anesthesia: Advantages, Challenges, and Future Directions
Background: Neuromuscular blocking agents play an important role in modern anesthesia by facilitating optimal surgical conditions through deep muscle relaxation. Additionally, neuromuscular monitoring and reversal ensure swift and reliable recovery from neuromuscular blockade. The evolution of neuromuscular blocking agents, from early curare derivatives to contemporary agents such as rocuronium and cisatracurium, has significantly enhanced the safety and efficacy of anesthesia. Methods: This review examines the historical development, pharmacological mechanisms, clinical applications, and innovations in managing neuromuscular blockade. Results: It underscores key milestones in the advancement of neuromuscular blockade, including the introduction of neuromuscular monitoring techniques like Train-of-Four, which improve patient safety by reducing residual neuromuscular blockade. Pharmacological advancements, particularly the emergence of sugammadex, have further revolutionized clinical practice by enabling rapid and reliable reversal of steroidal neuromuscular blocking agents. The discussion covers the role of deep neuromuscular blockade in optimizing surgical conditions, especially in minimally invasive procedures. Conclusion: Comparative analyses of standard versus deep blockade reveal potential advantages in certain surgical scenarios, although patient-specific factors and associated risks must be carefully evaluated. Future directions involve developing innovative neuromuscular blocking agents and reversal agents aimed at achieving faster onset, shorter duration, and fewer side effects. The management of neuromuscular blockade continues to evolve, propelled by advancements in pharmacology and monitoring technology. Anesthesiologists should embrace a personalized approach, integrating advanced monitoring tools and customized pharmacological strategies to enhance patient outcomes. Ongoing research into next-generation neuromuscular blocking agents and reversal agents holds the promise of further improving safety and efficiency in anesthesia practice.
- Open Access
- 5 February 2025
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 69 (3) , e14589
Intubating conditions during rapid sequence induction with either rocuronium or suxamethonium in elderly patients. A randomised study
Background: During rapid sequence induction, either rocuronium 1.0 mg kg−1 or suxamethonium 1.0 mg kg−1 can be administered to facilitate endotracheal intubation. We hypothezised that rocuronium provided a larger proportion of excellent intubating conditions compared to suxamethonium in elderly patients.Methods: A total of 90 patients 80 years or above with American Society of Anesthesiologists physical health Classes I–IV, and a body mass index < 35 kg m−1−2 were randomised to either rocuronium 1.0 mg kg−1 or suxamethonium 1.0 mg kg−1 during rapid sequence induction with intubation using a video laryngoscope. After 60 s, tracheal intubating conditions were evaluated using the Fuchs‐Buder scale by a blinded investigator, and the primary outcome was the proportion of patients with excellent intubating conditions. Further outcomes included first pass success rate, intubating conditions according to the intubating difficulty scale (IDS), onset time and postoperative occurrence of muscle soreness, hoarseness and sore throat.Results: All patients were evaluated for the primary outcome. Excellent intubating conditions occurred in 36 patients (73%) versus 31 (75%) in the rocuronium group and suxamethonium group, respectively (95% confidence interval [CI]: −16 to 20) (p = .82). The first pass success rate was 48 (98%) versus 40 (98%) comparing the rocuronium group with the suxamethonium group, respectively (p = .90). No difference in IDS score was found; median 0 (interquartile ranges [IQR]: 0–1) versus median 0 (IQR: 0–1) (p = .48). Onset time was significantly shorter in the suxamethonium group 99 versus 131 s (p = .01) (95% CI: 7 to 57). Finally, no difference was found in the occurrence of muscle soreness, hoarseness or sore throat postoperatively.Conclusion: No important difference in intubating conditions was found during rapid sequence induction after the administration of either rocuronium 1.0 mg kg−1 or suxamethonium 1.0 mg kg−1 in patients 80 years or above.Editorial Comment: This reports a superiority trial comparing standardised doses of rocuronium and suxamethonium at 60 s for quality of intubating conditions in the rapid sequence context, and this in an elderly cohort. The findings showed no difference between the drugs concerning intubation outcomes, though the onset or time to peak effect was shorter for suxamethonium, again demonstrated in a cohort 80 years old or older.
- 5 February 2025
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 69 (3) , e14589
Open AccessIntubating conditions during rapid sequence induction with either rocuronium or suxamethonium in elderly patients. A randomised study
Background: During rapid sequence induction, either rocuronium 1.0 mg kg−1 or suxamethonium 1.0 mg kg−1 can be administered to facilitate endotracheal intubation. We hypothezised that rocuronium provided a larger proportion of excellent intubating conditions compared to suxamethonium in elderly patients.Methods: A total of 90 patients 80 years or above with American Society of Anesthesiologists physical health Classes I–IV, and a body mass index < 35 kg m−1−2 were randomised to either rocuronium 1.0 mg kg−1 or suxamethonium 1.0 mg kg−1 during rapid sequence induction with intubation using a video laryngoscope. After 60 s, tracheal intubating conditions were evaluated using the Fuchs‐Buder scale by a blinded investigator, and the primary outcome was the proportion of patients with excellent intubating conditions. Further outcomes included first pass success rate, intubating conditions according to the intubating difficulty scale (IDS), onset time and postoperative occurrence of muscle soreness, hoarseness and sore throat.Results: All patients were evaluated for the primary outcome. Excellent intubating conditions occurred in 36 patients (73%) versus 31 (75%) in the rocuronium group and suxamethonium group, respectively (95% confidence interval [CI]: −16 to 20) (p = .82). The first pass success rate was 48 (98%) versus 40 (98%) comparing the rocuronium group with the suxamethonium group, respectively (p = .90). No difference in IDS score was found; median 0 (interquartile ranges [IQR]: 0–1) versus median 0 (IQR: 0–1) (p = .48). Onset time was significantly shorter in the suxamethonium group 99 versus 131 s (p = .01) (95% CI: 7 to 57). Finally, no difference was found in the occurrence of muscle soreness, hoarseness or sore throat postoperatively.Conclusion: No important difference in intubating conditions was found during rapid sequence induction after the administration of either rocuronium 1.0 mg kg−1 or suxamethonium 1.0 mg kg−1 in patients 80 years or above.Editorial Comment: This reports a superiority trial comparing standardised doses of rocuronium and suxamethonium at 60 s for quality of intubating conditions in the rapid sequence context, and this in an elderly cohort. The findings showed no difference between the drugs concerning intubation outcomes, though the onset or time to peak effect was shorter for suxamethonium, again demonstrated in a cohort 80 years old or older.
- 2 January 2025
- Published by Springer Nature in Current Anesthesiology Reports
- Vol. 15 (1) , 1-5
Pharmacodynamics of Neuromuscular Blocking Agents in Different Muscle Groups
- 2 January 2025
- Published by Springer Nature in Current Anesthesiology Reports
- Vol. 15 (1) , 1-5
Pharmacodynamics of Neuromuscular Blocking Agents in Different Muscle Groups